IdarubicinVincristineCytarabine and daunorubicinAnthracycline drugVyxeosReceived induction chemotherapyGranulocyte-ColonyTherapyPost induction chemotherapyAnthracyclinesPrednisoloneEtoposideVenetoclaxRegimenMitoxantroneSurvivalTherapeuticAcute promyelocGemtuzumab ozogamicinGlucocorticoidCombinationEfficacyInhibitorDosesDaysTreatmentMidostaurinNewly-diagnosedToxicityApoptosisCompleteIntensificationStandardConventional inductionAdultsPhaseLeukemia
Idarubicin7
- This phase III trial comparing idarubicin with high-dose daunorubicin as part of induction therapy in AML did not find significant differences in complete remission rates, relapse, or survival. (ascopost.com)
- A significant interaction between the treatment arm and the FLT3-ITD mutation was found, and high-dose daunorubicin was more effective than idarubicin in patients with FLT3-ITD mutation. (ascopost.com)
- Standard dosage of cytarabine is given on a consistent basis for 7 days and then an anthracycline drug, such as daunorubicin or idarubicin, is administered for 3 days. (pharmacytimes.com)
- Idarubicin hydrochloride is a DNA-intercalating analog of daunorubicin which has an inhibitory effect on nucleic acid synthesis and interacts with the enzyme topoisomerase II. (nih.gov)
- Anthracyclines, e. g. daunorubicin, doxorubicin, and idarubicin, consist of a tetracycline moiety linked via a glycosidic bond to a sugar residue, usually the aminosugar daunosamine. (lu.se)
- idarubicin instead of daunorubicin enhances the long-term efficacy of chemotherapy. (sciencepop.org)
- Since the introduction of the anthracyclines (daunorubicin, idarubicin) and cytarabine, these therapeutic agents have been the cornerstones of remission induction therapy for adult AML. (ashpublications.org)
Vincristine3
- 2) intensive consolidation therapy including dasatinib, cyclophosphamide, daunorubicin, vincristine and prednisone, followed by 4 alternating cycles of 2 different consolidation therapy regimens. (cancertherapyadvisor.com)
- Drugs that commonly used in this stage are daunorubicin, vincristine, prednisolone and asparaginase. (submityourassignment.com)
- Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. (jalsg.jp)
Cytarabine and daunorubicin2
- Patients treated with CPX-351 had a median OS of 19.15 months as compared with 11.58 months for conventional formulations of cytarabine and daunorubicin. (medpagetoday.com)
- Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML. (lnox-team.org)
Anthracycline drug1
- Doctors may use a combination of chemotherapy drugs, such as cytarabine, and an anthracycline drug, such as daunorubicin. (medicalnewstoday.com)
Vyxeos6
- Median OS improved by almost 8 months among patients with AML and myelodysplasia-related changes (AML-MRC) treated with liposomal cytarabine-daunorubicin (CPX-351, Vyxeos) versus conventional 7 + 3 induction therapy, as reported at the Transplantation and Cellular Therapy Meetings . (medpagetoday.com)
- VYXEOS is a combination of 2 chemotherapies, daunorubicin and cytarabine, into tiny, bubble-like carriers called liposomes. (vyxeos.com)
- WARNING: VYXEOS has different dosage recommendations from other medications that contain daunorubicin and/or cytarabine. (vyxeos.com)
- Do not substitute VYXEOS for other daunorubicin and/or cytarabine-containing products. (vyxeos.com)
- VYXEOS should not be given to patients who have a history of serious allergic reaction to daunorubicin, cytarabine, or any of its ingredients. (vyxeos.com)
- VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. (vyxeospro.com)
Received induction chemotherapy1
- The patient received induction chemotherapy with daunorubicin and cytarabine and achieved remission, was treated with allogeneic bone marrow transplantation, but died 7 months after initial diagnosis. (ajmc.com)
Granulocyte-Colony3
- No increase of leukemia relapse in newly diagnosed patients with acute myeloidleukemia who received granulocyte colony-stimulating factor for life-threatening infection during remission induction and consolidation therapy. (jalsg.jp)
- A randomized controlled study of granulocyte colony stimulating factor after intensive induction and consolidation therapy in patients with acute lymphoblastic leukemia. (jalsg.jp)
- A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. (jalsg.jp)
Therapy31
- Gemtuzumab ozogamicin can be safely added to conventional induction therapy and provides a significant survival benefit for patients without adverse cytogenetic characteristics. (nih.gov)
- In 1973, daunorubicin (DNR) was shown to increase remission rates from 13 to 58% and to reduce hemorrhage-related mortality after 5 days of therapy relative to 6-MP-based regimens. (nature.com)
- Arm I (closed to accrual as of 4/2006): Patients receive same induction, consolidation, and interim maintenance therapy schedule as localized lymphoblastic lymphoma patients. (knowcancer.com)
- Patients receiving anti-CD20 monoclonal antibody therapy during induction therapy. (cincinnatichildrens.org)
- The faculty discuss the evolution of induction therapy options for younger patients with AML, as oncologists move from standard 7+3 (cytarabine/daunorubicin) chemotherapy to more personalized approaches. (ascopost.com)
- Patients were randomized (1:1) to receive induction therapy consisting of daunorubicin (60 mg/m2 on days 1 to 3) and cytarabine (200 mg/m2 on days 1 to 7) with (n=135) or without (n=136) gemtuzumab ozogamicin 3 mg/m2 (up to maximum of one vial) on days 1, 4, and 7. (fda.gov)
- Patients with no evidence of disease progression or significant toxicities after induction received continuation therapy as outpatients with up to 8 courses of treatment including gemtuzumab ozogamicin 2 mg/m2 on day 1, every 4 weeks. (fda.gov)
- To determine the tolerability of combination therapy with ruxolitinib and Early Intensification therapy in patients with activation of JAK-STAT signaling that can be inhibited by ruxolitinib and Day 15 or Day 22 MRD ≥5%, Day 42 MRD ≥1%, or LLy patients without complete response at the End of Induction and all patients with early T cell precursor leukemia. (centerwatch.com)
- Principal supporting data for the approval came from the phase III QUAZAR AML-001 trial, a placebo-controlled trial involving 472 patients, ages 55 or older, with transplant-ineligible AML in first remission after standard induction therapy. (medpagetoday.com)
- A treatment course including Mylotarg in combination therapy for adults with newly-diagnosed de novo CD33-positive AML consists of 1 induction cycle and 2 consolidation cycles. (centerwatch.com)
- A treatment course of Mylotarg as a single agent for adults with newly-diagnosed CD33-positive AML consists of 1 cycle of induction and up to 8 cycles of continuation therapy. (centerwatch.com)
- Treatment includes induction therapy and postremission therapy (consolidation). (medscape.com)
- There are 2 forms of treatment for AML: induction therapy for complete remission (CR) and consolidation therapy to maintain CR. (pharmacytimes.com)
- After induction therapy, a patient is given consolidation therapy done with high-dose cytarabine. (pharmacytimes.com)
- Treatment of APL includes induction therapy, consolidation therapy, and maintenance therapy. (medscape.com)
- For low- and intermediate-risk patients, induction therapy should consist of ATRA and arsenic trioxide (ATO) without chemotherapy. (medscape.com)
- Induction therapy should not be modified based on the presence of leukemia cell characteristics that have variably been considered to predict a poorer prognosis (eg, secondary chromosomal abnormalities, FLT3 mutations, CD56 expression, BCR3 PML-RARA isoform). (medscape.com)
- Consolidation therapy is based on the potential risk of relapse in patients who undergo induction therapy. (medscape.com)
- Panels A through D show examples of different patterns of clearance of leukemia-associated mutations after induction therapy in 4 acute myeloid leukemia cases. (jamanetwork.com)
- While the standard-of-care in Japan for the treatment of younger patients with newly diagnosed Ph+ ALL is allo-HSCT preceded by imatinib plus intensive chemotherapy induction therapy, 30% to 40% of patients treated with this regimen in clinical trials were unable to undergo allo-HSCT due to older age, early relapse, or therapy-related death. (cancertherapyadvisor.com)
- Previously reported results demonstrated that both 3-year EFS and 3-year OS were improved for the overall study population of patients with newly diagnosed Ph+ ALL receiving dasatinib-based therapy compared with imatinib-based induction therapy. (cancertherapyadvisor.com)
- The rate of HCR after induction therapy was 100%, and 21.8%, 52.6% and 57.7% achieved molecular complete remission (MCR) after induction therapy, intensive consolidation therapy, and the first cycle of consolidation therapy, respectively. (cancertherapyadvisor.com)
- No induction therapy-related deaths were reported. (cancertherapyadvisor.com)
- A cross-study comparison of these results with the PH+ALL202 study involving imatinib-based induction therapy did not show significant differences in these rates. (cancertherapyadvisor.com)
- Typically, chemotherapy treatment is given to the patient in cycles and in phases: induction, consolidation and maintenance therapy. (submityourassignment.com)
- Induction therapy is the initial treatment of the chemotherapy that aimed to destroy as many leukemia cells as possible, achieve normal level of blood counts and treat acute lymphocytic leukemia into remission. (submityourassignment.com)
- Induction therapy is usually very intense and lasts about one month. (submityourassignment.com)
- Additionally, therapy has significant toxicity, with induction death rates ~20% even in younger patients (Juliusson et al. (ox.ac.uk)
- I. To determine if the administration of post-Induction age-adjusted intrathecal triple therapy (ITT) on a Modified Berlin-Frankfurt-Munster (MBFM) interim maintenance high-dose methotrexate (IMHDM) backbone will improve 5-year disease-free survival (DFS) of children with high-risk (HR) B-acute lymphoblastic leukemia (ALL) compared to age-adjusted intrathecal (IT) methotrexate (MTX). (uchicagomedicine.org)
- Improved induction therapy could yield more CRs or CRs of longer duration. (ashpublications.org)
- Randomized study of individualized induction therapy with or without VCR, and of maintenance 4 or 12 courses in adult AML: JALSG-AML87. (jalsg.jp)
Post induction chemotherapy1
- Only patients with KMT2A-R continue to post-induction chemotherapy. (iu.edu)
Anthracyclines1
- The anthracyclines are efficient chemotherapeutic agents against cancer, but their use is limited due to cardiotoxicity and induction of multidrug resistance. (lu.se)
Prednisolone1
- Changes in the MRC ALL97 trial within the study period resulted in some Ph+ ALL receiving daunorubicin and either prednisolone or dexamethasone during induction. (johnshopkins.edu)
Etoposide1
- Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities. (ox.ac.uk)
Venetoclax1
- The Company is also conducting a series of studies to evaluate ziftomenib in combination with current standards of care, beginning with venetoclax/azacitidine and standard induction cytarabine/daunorubicin chemotherapy in NPM1-mutant and KMT2A-rearranged newly diagnosed and relapsed/refractory AML (KOMET-007). (abc4.com)
Regimen4
- The traditional regimen for induction chemotherapy, irrespective of favorable intermediate or unfavorable-risk AML, is the 7+3 regimen. (pharmacytimes.com)
- This analysis focused on the allo-HSCT-related end points in a study of patients with newly diagnosed Ph+ ALL treated with a 2-step dasatinib-containing induction regimen. (cancertherapyadvisor.com)
- Results from a phase 2 study showed that a 2-step induction regimen involving dasatinib and intensive chemotherapy was associated with high rates of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients younger than 65 years with Philadelphia chromosome-positive (Ph+), newly diagnosed acute lymphoblastic leukemia (ALL), as well as improved 3-year overall survival (OS) rates for those undergoing allo-HSCT compared with those who did not. (cancertherapyadvisor.com)
- For instance, patients with AML often receive an induction chemotherapy regimen called 7+3 (7 days of cytarabine and 3 days of daunorubicin). (inmunebio.com)
Mitoxantrone1
- Instead of anthracyclins, remission induction programs may incorporate mitoxantrone and amsacrine. (ashpublications.org)
Survival2
- The primary study endpoint was 3-year event-free survival (EFS) following induction. (cancertherapyadvisor.com)
- In their concluding remarks, the study authors noted that "this study demonstrated [dasatinib]-combined 2-step induction improved pretransplant treatment, which facilitated [allo-HSCT] and resulted in significantly improved survival. (cancertherapyadvisor.com)
Therapeutic1
- Similarly studies with Emodin and Aloe emodin derivatives have also revealed greater therapeutic potential, DNA intercalation property, and reactive oxygen species generation and thereby induction of apoptosis in cancer cells [ 12 ]. (longdom.org)
Acute promyeloc1
- We searched PubMed for reports of randomised controlled trials published in any language up to May 1, 2013, that included an assessment of gemtuzumab ozogamicin given to adults (aged 15 years and older) in conjunction with the first course of intensive induction chemotherapy for acute myeloid leukaemia (excluding acute promyelocytic leukaemia) compared with chemotherapy alone. (nih.gov)
Gemtuzumab ozogamicin3
- We did a meta-analysis of individual patient data to assess the efficacy of adding gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia. (nih.gov)
- Gemtuzumab ozogamicin may be used in combination with daunorubicin and cytarabine for adults with newly-diagnosed AML, or as a stand-alone treatment for certain adult and pediatric patients. (fda.gov)
- During induction, gemtuzumab ozogamicin 6 mg/m2 was given on day 1 and gemtuzumab ozogamicin 3 mg/m2 was given on day 8. (fda.gov)
Glucocorticoid1
- In addition, CBR1 may play a critical role in prostaglandin F2α (PGF2α) synthesis in human amnion fibroblasts, and cortisol promotes the conversion of PGE2 into PGF2α via glucocorticoid receptor (GR)-mediated induction of CBR1 in human amnion fibroblasts. (wikipedia.org)
Combination1
- Early studies with induction including 6-mercatopurine (6-MP) alone or in combination with steroids, methyl-glyoxal guanyl hydrazine and/or methotrexate led to poor results. (nature.com)
Efficacy1
- Continuous efforts are being made to improve the efficacy of remission induction treatment. (ashpublications.org)
Inhibitor2
- EA9181, A Phase III Randomized Trial of Steroids+Tyrosine Kinase Inhibitor Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults Rochester, Minn. This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. (mayo.edu)
- Based on our identified miRNA-regulated molecular machinery, an inhibitor of PDK1/Akt BX-912, an anthracycline antibiotic daunorubicin, and a multi-targeted protein kinase inhibitor midostaurin were discovered as potential repositioning drugs for treating lung cancer. (cdc.gov)
Doses2
- the ATO dosage is 0.15 mg/kg/day IV until bone marrow remission occurs (maximum induction, 60 doses). (medscape.com)
- EXPERIMENTAL DESIGN: Sixty patients with high-risk MDS or acute myeloid leukemia following MDS were treated with standard doses of daunorubicin and 1-beta-d-arabinofuranosylcytosine. (ox.ac.uk)
Days1
- The first is daunorubicin 60 mg for 3 days and ara-C for 7 days, so-called 7+3. (ascopost.com)
Treatment5
- Doctors may also recommend this treatment to those with relapsed or resistant AML after they undergo re-induction chemotherapy. (medicalnewstoday.com)
- A second induction may be given if you do not reach remission after the first treatment cycle. (vyxeos.com)
- Daunorubicin (DAN) is mostly used in the treatment of leukaemia and some solid tumour such as glioma. (farmaciajournal.com)
- Dr. Löwenberg describes upcoming possibilities for predicting prognosis in defined subsets by molecular markers and reviews experimental strategies to improve remission induction and postinduction treatment. (ashpublications.org)
- The treatment usually involves a remission induction phase aimed at establishing a complete remission and a postinduction phase aimed at eradicating "occult" residual disease. (ashpublications.org)
Midostaurin1
- For the study, patients were given either midostaurin or placebo in addition to standard daunorubicin/cytarabine chemotherapy during the induction stage. (incitasecurity.com)
Newly-diagnosed1
- OBJECTIVES: I. Assess the feasibility and outcome of intensified induction/consolidation followed by intensified re-induction/re-intensification in infants less than 1 year of age with newly diagnosed acute lymphocytic leukemia (ALL). (knowcancer.com)
Toxicity1
- I. To determine the toxicity and tolerability of post-Induction age-adjusted ITT compared to age-adjusted IT MTX in children with HR B-ALL. (uchicagomedicine.org)
Apoptosis2
- Flow cytometry study using Annexin V/Pi showed induction of apoptosis following RES, DAN and RES/DAN. (farmaciajournal.com)
- Taken together, RES and DAN showed synergistic effects in induction of apoptosis in leukaemia cell lines. (farmaciajournal.com)
Complete1
- Thirty-six (86%) achieved first complete remission (CR1) at the end of induction, of which 28 underwent BM transplantation (BMT). (johnshopkins.edu)
Intensification1
- Chemotherapy for AML is broken down into three phases: induction phase, consolidation (or intensification), and maintenance phase. (oncolink.org)
Standard2
- However, randomised trials in which it was combined with standard induction chemotherapy in adults have produced conflicting results. (nih.gov)
- Standard chemotherapy was cytarabine 100 mg/m 2 and daunorubicin 60 mg/m 2 . (vyxeos.com)
Conventional induction1
- This study was designed to assess the effect of methylation status on the outcome of conventional induction chemotherapy. (ox.ac.uk)
Adults1
- I. To determine if the reduction of minimal residual disease (MRD) from end-Induction to end-Consolidation is greater for children, adolescents, and young adults with VHR B-ALL receiving Experimental Arm 1 compared to the Control Arm. (uchicagomedicine.org)
Phase1
- Oral lesions were associated with the induction phase of chemotherapy. (bvsalud.org)
Leukemia1
- CLINICAL CASE: 7-year-old male schoolboy diagnosed with T-precursor acute lymphoid leukemia, finishing induction chemotherapy cycle with PETHEMA 2013 protocol. (bvsalud.org)